Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.
{"title":"C-X-C motif chemokine ligand 12-C-X-C chemokine receptor type 4 signaling axis in cancer and the development of chemotherapeutic molecules.","authors":"Jui-Hung Yen, Chun-Chun Chang, Hao-Jen Hsu, Chin-Hao Yang, Hemalatha Mani, Je-Wen Liou","doi":"10.4103/tcmj.tcmj_52_24","DOIUrl":"10.4103/tcmj.tcmj_52_24","url":null,"abstract":"<p><p>Chemokines are small, secreted cytokines crucial in the regulation of a variety of cell functions. The binding of chemokine C-X-C motif chemokine ligand 12 (CXCL12) (stromal cell-derived factor 1) to a G-protein-coupled receptor C-X-C chemokine receptor type 4 (CXCR4) triggers downstream signaling pathways with effects on cell survival, proliferation, chemotaxis, migration, and gene expression. Intensive and extensive investigations have provided evidence suggesting that the CXCL12-CXCR4 axis plays a pivotal role in tumor development, survival, angiogenesis, metastasis, as well as in creating tumor microenvironment, thus implying that this axis is a potential target for the development of cancer therapies. The structures of CXCL12 and CXCR4 have been resolved with experimental methods such as X-ray crystallography, NMR, or cryo-EM. Therefore, it is possible to apply structure-based computational approaches to discover, design, and modify therapeutic molecules for cancer treatments. Here, we summarize the current understanding of the roles played by the CXCL12-CXCR4 signaling axis in cellular functions linking to cancer progression and metastasis. This review also provides an introduction to protein structures of CXCL12 and CXCR4 and the application of computer simulation and analysis in understanding CXCR4 activation and antagonist binding. Furthermore, examples of strategies and current progress in CXCL12-CXCR4 axis-targeted development of therapeutic anticancer inhibitors are discussed.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"231-239"},"PeriodicalIF":1.4,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-24eCollection Date: 2024-07-01DOI: 10.4103/tcmj.tcmj_28_24
Der-Shan Sun, Hsin-Hou Chang
Extracellular vesicles (EVs) have emerged as key players in intercellular communication, disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs are now recognized as vital mediators of cell-to-cell communication, ferrying a cargo of proteins, nucleic acids, and lipids, providing cellular resilience in response to stresses. This review provides a comprehensive overview of EVs, focusing on their role as biomarkers in disease diagnosis, their functional significance in physiological and pathological processes, and the potential of bioengineering for therapeutic applications. EVs offer a promising avenue for noninvasive disease diagnosis and monitoring, reflecting the physiological state of originating cells. Their diagnostic potential spans a spectrum of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. Moreover, their presence in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their diagnostic utility, presenting advantages over traditional methods. Beyond diagnostics, EVs mediate crucial roles in intercellular communication, facilitating the transfer of bioactive molecules between cells. This communication modulates various physiological processes such as tissue regeneration, immune modulation, and neuronal communication. Dysregulation of EV-mediated communication is implicated in diseases such as cancer, immune disorders, and neurodegenerative diseases, highlighting their therapeutic potential. Bioengineering techniques offer avenues for manipulating EVs for therapeutic applications, from isolation and purification to engineering cargo and targeted delivery systems. These approaches hold promise for developing novel therapeutics tailored to specific diseases, revolutionizing personalized medicine. However, challenges such as standardization, scalability, and regulatory approval need addressing for successful clinical translation. Overall, EVs represent a dynamic frontier in biomedical research with vast potential for diagnostics, therapeutics, and personalized medicine.
{"title":"Extracellular vesicles: Function, resilience, biomarker, bioengineering, and clinical implications.","authors":"Der-Shan Sun, Hsin-Hou Chang","doi":"10.4103/tcmj.tcmj_28_24","DOIUrl":"10.4103/tcmj.tcmj_28_24","url":null,"abstract":"<p><p>Extracellular vesicles (EVs) have emerged as key players in intercellular communication, disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs are now recognized as vital mediators of cell-to-cell communication, ferrying a cargo of proteins, nucleic acids, and lipids, providing cellular resilience in response to stresses. This review provides a comprehensive overview of EVs, focusing on their role as biomarkers in disease diagnosis, their functional significance in physiological and pathological processes, and the potential of bioengineering for therapeutic applications. EVs offer a promising avenue for noninvasive disease diagnosis and monitoring, reflecting the physiological state of originating cells. Their diagnostic potential spans a spectrum of diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. Moreover, their presence in bodily fluids such as blood, urine, and cerebrospinal fluid enhances their diagnostic utility, presenting advantages over traditional methods. Beyond diagnostics, EVs mediate crucial roles in intercellular communication, facilitating the transfer of bioactive molecules between cells. This communication modulates various physiological processes such as tissue regeneration, immune modulation, and neuronal communication. Dysregulation of EV-mediated communication is implicated in diseases such as cancer, immune disorders, and neurodegenerative diseases, highlighting their therapeutic potential. Bioengineering techniques offer avenues for manipulating EVs for therapeutic applications, from isolation and purification to engineering cargo and targeted delivery systems. These approaches hold promise for developing novel therapeutics tailored to specific diseases, revolutionizing personalized medicine. However, challenges such as standardization, scalability, and regulatory approval need addressing for successful clinical translation. Overall, EVs represent a dynamic frontier in biomedical research with vast potential for diagnostics, therapeutics, and personalized medicine.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"251-259"},"PeriodicalIF":1.4,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Discectomy is the most common surgery for lumbar herniated intervertebral disc (HIVD) disease. However, 5%-24% of patients undergo a second surgery due to recurrent disc herniation.
Materials and methods: This study was aimed to identify the risk factors for reoperation after discectomy of lumbar HIVD and recommend treatment for patients with a high risk of reoperation. We recruited patients diagnosed as having single-level lumbar HIVD who underwent open discectomy from January 1, 2000, to December 31, 2012 in our hospital. We used a survival curve to inspect the survival time and reoperation rate after surgery. We discussed the correlation of reoperation rate with discectomy level, body mass index, heavy lifting after surgery, sex, and age. Furthermore, we investigated the correlation between the experience of a surgeon and the reoperation rate.
Results: A total of 619 patients were enrolled in our study. Most patients were 40-60 years old (48.8%), and most of them had herniation at L4/5 level (48.9%). The 8-year survival rate was 92%. Weight lifting after surgery may increase the reoperation rate by 115 and 18 times for those >60 years and <40 years, respectively. In addition, less experience of the surgeon and female sex had a high reoperation rate.
Conclusion: Postoperative working modification may be very important for preventing patients from recurrent HIVD. For elderly people with HIVD, a more conservative therapy could be selected. If patients with lumbar spine hypermobility or severe degeneration require wide laminectomy, primary fusion should be considered.
{"title":"Risk factors for reoperation after discectomy of lumbar herniated intervertebral disc disease.","authors":"Cheng-Huan Peng, Ing-Ho Chen, Tzai-Chiu Yu, Jen-Hung Wang, Wen-Tien Wu, Kuang-Ting Yeh","doi":"10.4103/tcmj.tcmj_206_23","DOIUrl":"10.4103/tcmj.tcmj_206_23","url":null,"abstract":"<p><strong>Objectives: </strong>Discectomy is the most common surgery for lumbar herniated intervertebral disc (HIVD) disease. However, 5%-24% of patients undergo a second surgery due to recurrent disc herniation.</p><p><strong>Materials and methods: </strong>This study was aimed to identify the risk factors for reoperation after discectomy of lumbar HIVD and recommend treatment for patients with a high risk of reoperation. We recruited patients diagnosed as having single-level lumbar HIVD who underwent open discectomy from January 1, 2000, to December 31, 2012 in our hospital. We used a survival curve to inspect the survival time and reoperation rate after surgery. We discussed the correlation of reoperation rate with discectomy level, body mass index, heavy lifting after surgery, sex, and age. Furthermore, we investigated the correlation between the experience of a surgeon and the reoperation rate.</p><p><strong>Results: </strong>A total of 619 patients were enrolled in our study. Most patients were 40-60 years old (48.8%), and most of them had herniation at L4/5 level (48.9%). The 8-year survival rate was 92%. Weight lifting after surgery may increase the reoperation rate by 115 and 18 times for those >60 years and <40 years, respectively. In addition, less experience of the surgeon and female sex had a high reoperation rate.</p><p><strong>Conclusion: </strong>Postoperative working modification may be very important for preventing patients from recurrent HIVD. For elderly people with HIVD, a more conservative therapy could be selected. If patients with lumbar spine hypermobility or severe degeneration require wide laminectomy, primary fusion should be considered.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"298-303"},"PeriodicalIF":1.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-30eCollection Date: 2024-07-01DOI: 10.4103/tcmj.tcmj_236_23
Meng-Yi Liu, Pei-Shan Hsu, Chiu-Feng Wu, Yao-Kuang Wu, Mei-Chen Yang, Wen-Lin Su, I-Shiang Tzeng, Chou-Chin Lan
Objectives: Endotracheal tube (ETT) intubation is a life-saving procedure in patients with respiratory failure. However, the presence of an ETT can cause significant discomfort. A tracheostomy tube is used to administer a mechanical ventilator, resulting in a more stable airway and fewer serious injuries. Noninvasive ventilators (NIPPVs) administer ventilation through masks and must be tightly fixed to the face. ETT, tracheostomy, and NIPPV are the most common methods of ventilator maintenance. However, these interventions often cause discomfort to patients. This study aimed to compare discomfort associated with ETT, tracheostomy, and NIPPV.
Materials and methods: Forty-nine conscious patients with postextubation NIPPV and eight conscious patients who underwent postextubation tracheotomy were evaluated for discomfort. A questionnaire survey on discomfort was performed before and after NIPPV or tracheostomy. These patients reported their level of discomfort on a visual analog scale.
Results: The levels of sore throat, nasal pain, body pain, activity limitation, respiratory discomfort, oral discomfort, difficulty coughing sputum, worry about respiratory tube disconnection, back pain, anxiety, worry about long-term admission, sleep disturbance, and general discomfort during ETT intubation were higher than during tracheostomy or NIPPV (all P < 0.05). The mean level of discomfort was approximately 5-6 points (moderate) in patients with ETT and 2-3 points (mild) in patients with NIPPV or tracheostomy.
Conclusion: The level of discomfort was higher in patients who underwent ETT intubation than in those who underwent NIPPV or tracheostomy. However, the level of discomfort was similar between the patients with NIPPV and those who underwent tracheostomy.
目的:气管内插管(ETT)是呼吸衰竭患者的一项救生程序。然而,气管内插管会给患者带来明显不适。气管插管用于使用机械呼吸机,可使气道更加稳定,减少严重损伤。无创呼吸机(NIPPV)通过面罩进行通气,必须紧紧固定在面部。ETT、气管切开术和 NIPPV 是最常见的呼吸机维护方法。然而,这些干预措施往往会给患者带来不适。本研究旨在比较与 ETT、气管切开术和 NIPPV 相关的不适感:对 49 名接受拔管后 NIPPV 的神志清醒患者和 8 名接受拔管后气管切开术的神志清醒患者进行了不适感评估。在 NIPPV 或气管切开术前后进行了不适感问卷调查。这些患者用视觉模拟量表报告了他们的不适程度:结果:在 ETT 插管期间,患者的咽喉疼痛、鼻腔疼痛、身体疼痛、活动受限、呼吸道不适、口腔不适、咳痰困难、担心呼吸管断开、背部疼痛、焦虑、担心长期入院、睡眠障碍和全身不适程度均高于气管切开术或 NIPPV 期间(所有 P <0.05)。ETT患者的平均不适程度约为5-6分(中度),NIPPV或气管切开患者的平均不适程度约为2-3分(轻度):结论:接受 ETT 插管的患者的不适程度高于接受 NIPPV 或气管切开术的患者。不过,NIPPV 患者和气管切开术患者的不适程度相似。
{"title":"The level of discomfort during the use of different circuits of the mechanical ventilator.","authors":"Meng-Yi Liu, Pei-Shan Hsu, Chiu-Feng Wu, Yao-Kuang Wu, Mei-Chen Yang, Wen-Lin Su, I-Shiang Tzeng, Chou-Chin Lan","doi":"10.4103/tcmj.tcmj_236_23","DOIUrl":"10.4103/tcmj.tcmj_236_23","url":null,"abstract":"<p><strong>Objectives: </strong>Endotracheal tube (ETT) intubation is a life-saving procedure in patients with respiratory failure. However, the presence of an ETT can cause significant discomfort. A tracheostomy tube is used to administer a mechanical ventilator, resulting in a more stable airway and fewer serious injuries. Noninvasive ventilators (NIPPVs) administer ventilation through masks and must be tightly fixed to the face. ETT, tracheostomy, and NIPPV are the most common methods of ventilator maintenance. However, these interventions often cause discomfort to patients. This study aimed to compare discomfort associated with ETT, tracheostomy, and NIPPV.</p><p><strong>Materials and methods: </strong>Forty-nine conscious patients with postextubation NIPPV and eight conscious patients who underwent postextubation tracheotomy were evaluated for discomfort. A questionnaire survey on discomfort was performed before and after NIPPV or tracheostomy. These patients reported their level of discomfort on a visual analog scale.</p><p><strong>Results: </strong>The levels of sore throat, nasal pain, body pain, activity limitation, respiratory discomfort, oral discomfort, difficulty coughing sputum, worry about respiratory tube disconnection, back pain, anxiety, worry about long-term admission, sleep disturbance, and general discomfort during ETT intubation were higher than during tracheostomy or NIPPV (all <i>P</i> < 0.05). The mean level of discomfort was approximately 5-6 points (moderate) in patients with ETT and 2-3 points (mild) in patients with NIPPV or tracheostomy.</p><p><strong>Conclusion: </strong>The level of discomfort was higher in patients who underwent ETT intubation than in those who underwent NIPPV or tracheostomy. However, the level of discomfort was similar between the patients with NIPPV and those who underwent tracheostomy.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 3","pages":"311-318"},"PeriodicalIF":1.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11236071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-30eCollection Date: 2024-10-01DOI: 10.4103/tcmj.tcmj_233_23
Nicolas Daniel Widjanarko, Jonathan Christianto Subagya, Josephine Immanuel Maksi, Felicia Grizelda Suryatenggara, Sharon Claudia Ethelyn Sihole
Objectives: This systematic review aimed to summarize the benefit of apitherapy in human and animal models of asthma.
Materials and methods: The procedures in this review were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 protocol, where MEDLINE, ProQuest, and EBSCOhost databases were used to obtain eligible studies dating to 2023. Furthermore, the risk of bias was assessed using Risk of Bias Tool 2.0 (RoB-2) for randomized-control trials and Systematic Review Centre for Laboratory Animal Experimentation's RoB for animal studies.
Results: A total of 12 studies were included in the review based on the predetermined eligibility criteria, consisting of 4 human and 8 animal model reports. Among the four human studies, two had a low risk, while the other two had some concerns of bias. In the case of eight animal model of asthma, a total of three domains had a high risk of bias. Moreover, the anti-inflammatory properties of apitherapy were demonstrated by its capacity to inhibit NF-κB, nuclear factor of activated T cells, and IgE antibodies, leading to decreased production of tumor necrosis factor-α, interleukin-2 (IL-2), IL-6, and IL-8, and an increase in IL-10 levels. These beneficial effects were reported to be associated with improvements in clinical manifestations and lung function parameters in human subjects. The use of apitherapy was also related to the restoration of airway structure, and reduction of inflammatory cell infiltration, epithelial thickness, and mucus secretion in lung tissue of animal model of asthma.
Conclusion: Based on the results, apitherapy was effective in improving asthma symptoms and reducing inflammation in human and animal models of asthma.
目的:本系统综述旨在总结哮喘治疗对人类和动物模型的益处:本综述根据《2020年系统综述和荟萃分析首选报告项目》(Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 protocol)执行,使用MEDLINE、ProQuest和EBSCOhost数据库获取2023年前符合条件的研究。此外,随机对照试验采用偏倚风险工具 2.0(RoB-2)评估偏倚风险,动物研究采用实验室动物实验系统综述中心的 RoB 评估偏倚风险:根据预先确定的资格标准,共有 12 项研究被纳入审查范围,其中包括 4 项人体研究和 8 项动物模型报告。在 4 项人体研究中,有 2 项风险较低,而另外 2 项则存在一些偏倚问题。在 8 个哮喘动物模型中,共有 3 个领域存在高偏倚风险。此外,抗哮喘疗法的抗炎特性还体现在它能够抑制 NF-κB、活化 T 细胞核因子和 IgE 抗体,从而减少肿瘤坏死因子-α、白细胞介素-2(IL-2)、IL-6 和 IL-8 的产生,并提高 IL-10 的水平。据报道,这些有益效果与人体临床表现和肺功能参数的改善有关。哮喘动物模型肺组织中的炎症细胞浸润、上皮厚度和粘液分泌减少也与使用哮喘治疗法恢复气道结构有关:结论:根据研究结果,气道疗法能有效改善人类和动物哮喘模型的哮喘症状并减轻炎症反应。
{"title":"Utilization of apitherapy in allergic asthma: A systematic review of clinical and preclinical studies.","authors":"Nicolas Daniel Widjanarko, Jonathan Christianto Subagya, Josephine Immanuel Maksi, Felicia Grizelda Suryatenggara, Sharon Claudia Ethelyn Sihole","doi":"10.4103/tcmj.tcmj_233_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_233_23","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review aimed to summarize the benefit of apitherapy in human and animal models of asthma.</p><p><strong>Materials and methods: </strong>The procedures in this review were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 protocol, where MEDLINE, ProQuest, and EBSCOhost databases were used to obtain eligible studies dating to 2023. Furthermore, the risk of bias was assessed using Risk of Bias Tool 2.0 (RoB-2) for randomized-control trials and Systematic Review Centre for Laboratory Animal Experimentation's RoB for animal studies.</p><p><strong>Results: </strong>A total of 12 studies were included in the review based on the predetermined eligibility criteria, consisting of 4 human and 8 animal model reports. Among the four human studies, two had a low risk, while the other two had some concerns of bias. In the case of eight animal model of asthma, a total of three domains had a high risk of bias. Moreover, the anti-inflammatory properties of apitherapy were demonstrated by its capacity to inhibit NF-κB, nuclear factor of activated T cells, and IgE antibodies, leading to decreased production of tumor necrosis factor-α, interleukin-2 (IL-2), IL-6, and IL-8, and an increase in IL-10 levels. These beneficial effects were reported to be associated with improvements in clinical manifestations and lung function parameters in human subjects. The use of apitherapy was also related to the restoration of airway structure, and reduction of inflammatory cell infiltration, epithelial thickness, and mucus secretion in lung tissue of animal model of asthma.</p><p><strong>Conclusion: </strong>Based on the results, apitherapy was effective in improving asthma symptoms and reducing inflammation in human and animal models of asthma.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 4","pages":"440-451"},"PeriodicalIF":1.4,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11483089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142477331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Uremic pruritus (UP) is a prevalent and troublesome condition affecting individuals with end-stage renal failure, which results in intense pruritus, depression, as well as poor quality of sleep, significantly impacting their quality of life. According to previous studies, acupuncture and acupoint stimulation have been shown to provide additional benefits in treating UP in dialysis patients. In addition, using acupoints combination may yield superior effectiveness compared to utilizing a singular acupoint. To investigate the potential correlations between acupoint combinations, an association-rule analysis was employed.
Materials and methods: Apriori algorithms stand out as highly potent techniques for identifying associations in databases; this study utilized an association rule mining to examine the association rules of key acupoint groupings that could be employed for treating UP.
Results: The analysis utilized information derived from the meta-analysis encompassing 40 randomized controlled trials that used acupuncture to treat UP. In total, 64 acupoints were analyzed, and 71 association rules were found. The following acupoint combinations: Auricular shenmen (TF4), Quchi (LI11), and Geshu (BL17); Auricular heart (Extra14), Sanyinjiao (SP6), and Auricular lung (CO14); and Auricular heart (Extra14), Xuehai (SP10), and Auricular lung (CO14) showed the strongest associations.
Conclusion: Acupoints involving Auricular shenmen (TF4), Quchi (LI11), Geshu (BL17), Auricular heart (Extra14), Sanyinjiao (SP6), Auricular lung (CO14), and Xuehai (SP10) can be regarded as the core combination of acupuncture points for managing UP.
目的尿毒症瘙痒症(Uremic pruritus,UP)是终末期肾衰竭患者普遍存在的一种令人头疼的病症,会导致剧烈瘙痒、抑郁以及睡眠质量差,严重影响患者的生活质量。以往的研究表明,针灸和穴位刺激对治疗透析患者的瘙痒症有额外的益处。此外,与单个穴位相比,组合使用穴位可能会产生更好的疗效。为了研究穴位组合之间的潜在相关性,我们采用了关联规则分析法:Apriori算法是识别数据库中关联的高效技术;本研究利用关联规则挖掘法来研究可用于治疗UP的关键穴位组合的关联规则:该分析利用了荟萃分析(meta-analysis)中的信息,荟萃分析涵盖了40项使用针灸治疗UP的随机对照试验。共分析了 64 个穴位,发现了 71 条关联规则。以下是穴位组合:心包经(TF4)、曲池(LI11)和尺泽(BL17);心包经(Extra14)、三阴交(SP6)和肺俞(CO14);心包经(Extra14)、学海(SP10)和肺俞(CO14)的关联性最强:结论:耳穴神门(TF4)、曲池(LI11)、合谷(BL17)、心包经(Extra14)、三阴交(SP6)、肺俞(CO14)和学海(SP10)可视为调理 UP 的核心穴位组合。
{"title":"An Apriori algorithm-based association rule analysis to identify acupoint combinations for treating uremic pruritus.","authors":"Ping-Hsun Lu, Chien-Cheng Lai, Ling-Ya Chiu, I-Hsin Lin, Chih-Chin Iou, Po-Hsuan Lu","doi":"10.4103/tcmj.tcmj_217_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_217_23","url":null,"abstract":"<p><strong>Objective: </strong>Uremic pruritus (UP) is a prevalent and troublesome condition affecting individuals with end-stage renal failure, which results in intense pruritus, depression, as well as poor quality of sleep, significantly impacting their quality of life. According to previous studies, acupuncture and acupoint stimulation have been shown to provide additional benefits in treating UP in dialysis patients. In addition, using acupoints combination may yield superior effectiveness compared to utilizing a singular acupoint. To investigate the potential correlations between acupoint combinations, an association-rule analysis was employed.</p><p><strong>Materials and methods: </strong>Apriori algorithms stand out as highly potent techniques for identifying associations in databases; this study utilized an association rule mining to examine the association rules of key acupoint groupings that could be employed for treating UP.</p><p><strong>Results: </strong>The analysis utilized information derived from the meta-analysis encompassing 40 randomized controlled trials that used acupuncture to treat UP. In total, 64 acupoints were analyzed, and 71 association rules were found. The following acupoint combinations: Auricular shenmen (TF4), Quchi (LI11), and Geshu (BL17); Auricular heart (Extra14), Sanyinjiao (SP6), and Auricular lung (CO14); and Auricular heart (Extra14), Xuehai (SP10), and Auricular lung (CO14) showed the strongest associations.</p><p><strong>Conclusion: </strong>Acupoints involving Auricular shenmen (TF4), Quchi (LI11), Geshu (BL17), Auricular heart (Extra14), Sanyinjiao (SP6), Auricular lung (CO14), and Xuehai (SP10) can be regarded as the core combination of acupuncture points for managing UP.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 2","pages":"195-202"},"PeriodicalIF":1.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140866096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gastroesophageal reflux disease (GERD), a prevalent condition with multifactorial pathogenesis, involves esophageal motor dysmotility as a key contributing factor to its development. When suspected GERD patients have an inadequate response to proton-pump inhibitor (PPI) therapy and normal upper endoscopy results, high-resolution manometry (HRM) is utilized to rule out alternative diagnosis such as achalasia spectrum disorders, rumination, or supragastric belching. At present, HRM continues to provide supportive evidence for diagnosing GERD and determining the appropriate treatment. This review focuses on the existing understanding of the connection between esophageal motor findings and the pathogenesis of GERD, along with the significance of esophageal HRM in managing GERD patients. The International GERD Consensus Working Group introduced a three-step method, assessing the esophagogastric junction (EGJ), esophageal body motility, and contraction reserve with multiple rapid swallow (MRS) maneuvers. Crucial HRM abnormalities in GERD include frequent transient lower esophageal sphincter relaxations, disrupted EGJ, and esophageal body hypomotility. Emerging HRM metrics like EGJ-contractile integral and innovative provocative maneuver like straight leg raise have the potential to enhance our understanding of factors contributing to GERD, thereby increasing the value of HRM performed in patients who experience symptoms suspected of GERD.
{"title":"Esophageal motor abnormalities in gastroesophageal reflux disorders.","authors":"Wei-Yi Lei, Chih-Hsun Yi, Tso-Tsai Liu, Jui-Sheng Hung, Ming-Wun Wong, Chien-Lin Chen","doi":"10.4103/tcmj.tcmj_209_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_209_23","url":null,"abstract":"<p><p>Gastroesophageal reflux disease (GERD), a prevalent condition with multifactorial pathogenesis, involves esophageal motor dysmotility as a key contributing factor to its development. When suspected GERD patients have an inadequate response to proton-pump inhibitor (PPI) therapy and normal upper endoscopy results, high-resolution manometry (HRM) is utilized to rule out alternative diagnosis such as achalasia spectrum disorders, rumination, or supragastric belching. At present, HRM continues to provide supportive evidence for diagnosing GERD and determining the appropriate treatment. This review focuses on the existing understanding of the connection between esophageal motor findings and the pathogenesis of GERD, along with the significance of esophageal HRM in managing GERD patients. The International GERD Consensus Working Group introduced a three-step method, assessing the esophagogastric junction (EGJ), esophageal body motility, and contraction reserve with multiple rapid swallow (MRS) maneuvers. Crucial HRM abnormalities in GERD include frequent transient lower esophageal sphincter relaxations, disrupted EGJ, and esophageal body hypomotility. Emerging HRM metrics like EGJ-contractile integral and innovative provocative maneuver like straight leg raise have the potential to enhance our understanding of factors contributing to GERD, thereby increasing the value of HRM performed in patients who experience symptoms suspected of GERD.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 2","pages":"120-126"},"PeriodicalIF":1.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cerebrovascular accidents, also known as strokes, represent a major global public health challenge and contribute to substantial mortality, disability, and socioeconomic burden. Multidisciplinary approaches for poststroke therapies are crucial for recovering lost functions and adapting to new limitations. This review discusses the potential of neuromodulation techniques, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation, spinal cord stimulation (SCS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), as innovative strategies for facilitating poststroke recovery. Neuromodulation is an emerging adjunct to conventional therapies that target neural plasticity to restore lost function and compensate for damaged brain areas. The techniques discussed in this review have different efficacies in enhancing neural plasticity, optimizing motor recovery, and mitigating poststroke impairments. Specifically, rTMS has shown significant promise in enhancing motor function, whereas SCS has shown potential in improving limb movement and reducing disability. Similarly, VNS, typically used to treat epilepsy, has shown promise in enhancing poststroke motor recovery, while DBS may be used to improve poststroke motor recovery and symptom mitigation. Further studies with standardized protocols are warranted to elucidate the efficacy of these methods and integrate them into mainstream clinical practice to optimize poststroke care.
{"title":"Neuromodulation techniques in poststroke motor impairment recovery: Efficacy, challenges, and future directions.","authors":"Xiang-Ling Huang, Ming-Yung Wu, Ciou-Chan Wu, Lian-Cing Yan, Mei-Huei He, Yu-Chen Chen, Sheng-Tzung Tsai","doi":"10.4103/tcmj.tcmj_247_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_247_23","url":null,"abstract":"<p><p>Cerebrovascular accidents, also known as strokes, represent a major global public health challenge and contribute to substantial mortality, disability, and socioeconomic burden. Multidisciplinary approaches for poststroke therapies are crucial for recovering lost functions and adapting to new limitations. This review discusses the potential of neuromodulation techniques, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation, spinal cord stimulation (SCS), vagus nerve stimulation (VNS), and deep brain stimulation (DBS), as innovative strategies for facilitating poststroke recovery. Neuromodulation is an emerging adjunct to conventional therapies that target neural plasticity to restore lost function and compensate for damaged brain areas. The techniques discussed in this review have different efficacies in enhancing neural plasticity, optimizing motor recovery, and mitigating poststroke impairments. Specifically, rTMS has shown significant promise in enhancing motor function, whereas SCS has shown potential in improving limb movement and reducing disability. Similarly, VNS, typically used to treat epilepsy, has shown promise in enhancing poststroke motor recovery, while DBS may be used to improve poststroke motor recovery and symptom mitigation. Further studies with standardized protocols are warranted to elucidate the efficacy of these methods and integrate them into mainstream clinical practice to optimize poststroke care.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 2","pages":"136-141"},"PeriodicalIF":1.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-26eCollection Date: 2024-04-01DOI: 10.4103/tcmj.tcmj_267_23
Chien-Hao Wang, Jai-Sing Yang, Chao-Jung Chen, San-Hua Su, Hsin-Yuan Yu, Yu-Ning Juan, Yu-Jen Chiu, Tsung-Jung Ho
Objectives: The protective effects and related mechanisms of Jing-Si herbal tea (JSHT) were investigated in cellular damage mediated by pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, on normal human lung fibroblast by multiomic platform analysis.
Materials and methods: The insilico high-throughput target was analyzed using pharmacophore models by BIOVIA Discovery Studio 2022 with ingenuity pathway analysis software. To assess cell viability, the study utilized the MTT assay technique. In addition, the IncuCyte S3 ZOOM System was implemented for the continuous monitoring of cell confluence of JSHT-treated cytokine-injured HEL 299 cells. Cytokine concentrations were determined using a Quantibody Human Inflammation Array. Gene expression and signaling pathways were determined using next-generation sequencing.
Results: Insilico high-throughput target analysis of JSHT revealed ingenuity in canonical pathways and their networks. Glucocorticoid receptor signaling is a potential signaling of JSHT. The results revealed protective effects against the inflammatory cytokines on JSHT-treated HEL 299 cells. Transcriptome and network analyses revealed that induction of helper T lymphocytes, TNFSF12, NFKB1-mediated relaxin signaling, and G-protein coupled receptor signaling play important roles in immune regulatory on JSHT-treated cytokine-injured HEL 299 cells.
Conclusion: The findings from our research indicate that JSHT holds promise as a therapeutic agent, potentially offering advantageous outcomes in treating virus infections through various mechanisms. Furthermore, the primary bioactive components in JSHT justify extended research in antiviral drug development, especially in the context of addressing coronavirus.
{"title":"Protective effects of Jing-Si-herbal-tea in inflammatory cytokines-induced cell injury on normal human lung fibroblast <i>via</i> multiomic platform analysis.","authors":"Chien-Hao Wang, Jai-Sing Yang, Chao-Jung Chen, San-Hua Su, Hsin-Yuan Yu, Yu-Ning Juan, Yu-Jen Chiu, Tsung-Jung Ho","doi":"10.4103/tcmj.tcmj_267_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_267_23","url":null,"abstract":"<p><strong>Objectives: </strong>The protective effects and related mechanisms of Jing-Si herbal tea (JSHT) were investigated in cellular damage mediated by pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α, on normal human lung fibroblast by multiomic platform analysis.</p><p><strong>Materials and methods: </strong>The <i>in</i> <i>silico</i> high-throughput target was analyzed using pharmacophore models by BIOVIA Discovery Studio 2022 with ingenuity pathway analysis software. To assess cell viability, the study utilized the MTT assay technique. In addition, the IncuCyte S3 ZOOM System was implemented for the continuous monitoring of cell confluence of JSHT-treated cytokine-injured HEL 299 cells. Cytokine concentrations were determined using a Quantibody Human Inflammation Array. Gene expression and signaling pathways were determined using next-generation sequencing.</p><p><strong>Results: </strong><i>In</i> <i>silico</i> high-throughput target analysis of JSHT revealed ingenuity in canonical pathways and their networks. Glucocorticoid receptor signaling is a potential signaling of JSHT. The results revealed protective effects against the inflammatory cytokines on JSHT-treated HEL 299 cells. Transcriptome and network analyses revealed that induction of helper T lymphocytes, TNFSF12, NFKB1-mediated relaxin signaling, and G-protein coupled receptor signaling play important roles in immune regulatory on JSHT-treated cytokine-injured HEL 299 cells.</p><p><strong>Conclusion: </strong>The findings from our research indicate that JSHT holds promise as a therapeutic agent, potentially offering advantageous outcomes in treating virus infections through various mechanisms. Furthermore, the primary bioactive components in JSHT justify extended research in antiviral drug development, especially in the context of addressing coronavirus.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 2","pages":"152-165"},"PeriodicalIF":1.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-26eCollection Date: 2024-04-01DOI: 10.4103/tcmj.tcmj_276_23
Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang
Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged ≥61 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index ≥3 because of a higher risk of nonrelapse mortality.
{"title":"Recent advancements in hematopoietic stem cell transplantation in Taiwan.","authors":"Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang","doi":"10.4103/tcmj.tcmj_276_23","DOIUrl":"https://doi.org/10.4103/tcmj.tcmj_276_23","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival. In Taiwan, transplant donors showed remarkable growth from unrelated (24.8%) and haploidentical (10.5%) donors. The number of older patients (17.4%; aged ≥61 years) who underwent transplantation has increased markedly. This review summarizes several significant developments in HSCT treatment in Taiwan. First, the use of Anti-thymocyte globulin (ATG) and intravenous busulfan regimens were important risk factors for predicting hepatic sinusoidal obstruction syndrome. Second, a new, machine learning-based risk prediction scoring system for posttransplantation lymphoproliferative disorder has identified five risk factors: aplastic anemia, partially mismatched related donors, fludarabine use, ATG use, and acute skin graft-versus-host disease. Third, although the incidence of idiopathic pneumonia syndrome was low (1.1%), its mortality rate was high (58.1%). Fourth, difficult-to-treat mantle cell and T-cell lymphomas treated with autologous HSCT during earlier remission had higher survival rates. Fifth, treatment of incurable multiple myeloma with autologous HSCT showed a median progression-free survival and overall survival of 46.5 and 70.4 months, respectively. Sixth, different haploidentical transplantation strategies were compared. Seventh, caution should be taken in administering allogeneic HSCT treatment in older patients with myeloid leukemia with a Charlson Comorbidity Index ≥3 because of a higher risk of nonrelapse mortality.</p>","PeriodicalId":45873,"journal":{"name":"Tzu Chi Medical Journal","volume":"36 2","pages":"127-135"},"PeriodicalIF":1.5,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11025591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140857562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}